Change
Tools: Print  PDF Download Key Figures Comparison

Consolidated statement of income


 

 

 

 

Download XLS

 

 

 

 

 

 

 

 

 

 

 

In € millions

IFRS

NL GAAP1

 

2008

2007

2006

20052

2004

2003

2002

2001

2000

1999

1

The 1999 – 2003 figures have not been restated to IFRS accounting standards. The differences mainly relate to pensions and other post-retirement benefits, the recognition of deferred taxes on intercompany profit, and the recognition of goodwill. For the most part, the changed accounting is a matter of timing of the recognition of the assets, liabilities and related results.

2

The 1999 – 2005 figures have not been restated for the Organon BioSciences divestment.

3

Not meaningful as operating income is a loss.

 

 

 

 

 

 

 

 

 

 

 

Revenue

15,415

10,217

10,023

13,000

12,833

13,106

14,059

14,158

14,069

14,471

Operating income

(626)

747

859

1,486

1,527

1,064

1,362

1,198

1,487

525

Financing income and expenses

(183)

(120)

(106)

(156)

(144)

(166)

(204)

(257)

(245)

(245)

Income tax

(260)

(166)

(96)

(338)

(412)

(254)

(335)

(294)

(395)

(106)

Results from associates and joint ventures

25

(20)

87

6

10

7

30

55

143

40

Profit for the period from continuing operations

(1,044)

441

744

998

981

651

853

702

990

214

 

 

 

 

 

 

 

 

 

 

 

Minority interests attributable to minority shareholders

(65)

(31)

(29)

(37)

(36)

(49)

(35)

(31)

(43)

(25)

Discontinued operations

23

8,920

438

Net income, attributable to the shareholders

(1,086)

9,330

1,153

961

945

602

818

671

947

189

 

 

 

 

 

 

 

 

 

 

 

Common shares,
in € millions at December 31

231.7

262.3

287.0

285.8

285.8

285.7

285.7

285.9

285.9

285.9

Dividend

417

472

344

343

343

343

343

343

343

286

 

 

 

 

 

 

 

 

 

 

 

Number of employees
at December 31

60,000

42,600

42,700

61,300

61,400

64,600

67,900

66,300

68,400

68,000

Salaries, wages, and other employee benefits

3,022

2,215

2,158

3,221

3,216

3,505

3,552

3,416

3,285

3,777

Salaries, wages, and other employee benefits in percent of revenue

19.6

21.7

21.5

24.8

25.1

26.7

25.3

24.1

23.3

26.1

 

 

 

 

 

 

 

 

 

 

 

Ratios

 

 

 

 

 

 

 

 

 

 

Operating income
in percent of revenue

(4.1)

7.3

8.6

11.4

11.9

8.1

9.7

8.5

10.6

3.6

Operating income
in percent of invested capital

3

14.0

15.8

19.3

20.0

12.7

15.1

12.8

16.7

5.9

Net income
in percent of shareholders’ equity

3

122.9

30.5

32.0

40.6

26.2

32.9

24.1

39.7

9.0

 

 

 

 

 

 

 

 

 

 

 

Interest coverage

3

6.2

8.1

9.5

10.6

6.4

6.7

4.7

6.1

2.1

EBITDA coverage

3

9.2

11.6

13.2

14.5

10.3

10.0

7.3

8.8

5.3

 

 

 

 

 

 

 

 

 

 

 

Per share information

 

 

 

 

 

 

 

 

 

 

Net income

(4.38)

33.82

4.02

3.36

3.31

2.11

2.86

2.35

3.31

0.66

Dividend

1.80

1.80

1.20

1.20

1.20

1.20

1.20

1.20

1.20

1.00

Shareholders’ equity

32.21

42.06

14.44

11.95

9.12

8.76

7.34

10.07

9.42

7.28

 

 

 

 

 

 

 

 

 

 

 

Highest share price during the year

57.11

65.56

49.41

40.18

33.79

32.44

54.50

57.85

59.15

52.40

Lowest share price during the year

22.85

44.41

38.30

30.82

24.87

16.00

27.25

33.73

37.30

30.00

Year-end share price

29.44

54.79

46.18

39.15

31.38

30.60

30.23

50.15

57.20

49.80

For definitions of certain financial ratios and concepts see the full glossary.

Keyword Search
Copyright © 2009 Akzo Nobel N.V.